Cryoport, Inc.: management transactions · United States · SEC (Form 4)

About Cryoport, Inc.

Cryoport, Inc. (ticker: CYRX) is a U.S.-based company listed on the NASDAQ market in the United States, with a business model focused on temperature-controlled supply chain solutions for the life sciences industry. Headquartered in Brentwood, Tennessee, and founded in 1999, Cryoport has evolved from a specialized cryogenic shipping business into an integrated platform serving biopharmaceutical companies, cell and gene therapy developers, and other advanced life sciences customers. The company’s value proposition is built around protecting highly sensitive biological materials throughout the chain of custody, from origin to final destination. ([cryoport.com](https://www.cryoport.com/about-us/cryoports-family-of-companies/?utm_source=openai)) Cryoport’s operations are organized around a family of complementary businesses, including Cryoport Systems, MVE Biological Solutions, and CRYOGENE. Together, these units provide advanced packaging, specialty logistics services, informatics and monitoring, biostorage services, cryopreservation-related capabilities, and cryogenic equipment. This integrated structure is important because the company does not compete solely as a transportation provider; instead, it positions itself as a platform that supports the full lifecycle of advanced therapy supply chains. Its offerings are particularly relevant for cell therapy, gene therapy, biologics, regenerative medicine, and other temperature-sensitive applications where product integrity, compliance, and traceability are critical. ([cryoport.com](https://www.cryoport.com/about-us/cryoports-family-of-companies/?utm_source=openai)) From a competitive standpoint, Cryoport occupies a niche but strategically attractive segment. The company’s differentiation lies in its specialized infrastructure, regulatory-oriented service model, and end-to-end supply chain capabilities. In advanced therapies, customers often require more than standard freight execution: they need validated packaging, continuous condition monitoring, GMP-compliant storage, and logistics expertise tailored to fragile biological products. That makes the market more relationship-driven and more technically demanding than conventional logistics. Cryoport’s positioning reflects this, with an emphasis on becoming a trusted platform partner rather than a commoditized shipping vendor. ([cryoport.com](https://www.cryoport.com/about-us/cryoports-family-of-companies/?utm_source=openai)) Geographically, Cryoport has expanded beyond its U.S. base and is increasingly international. Recent initiatives have included the acquisition of Cell&Co BioServices and the launch of a facility near Paris, highlighting its strategy to strengthen its European footprint and support clients across key life sciences hubs. That global expansion is particularly relevant because advanced therapy development is a multinational activity, with clinical programs, manufacturing, and commercialization often spread across the United States, Europe, and other regions. ([cryoport.com](https://www.cryoport.com/cryoport-expands-global-supply-chain-network-through-recent-acquisition-of-cellco-bioservices/?utm_source=openai)) Recent company updates underline the momentum in its core markets. In 2025, Cryoport highlighted industry recognition for its cell and gene therapy supply-chain capabilities, as well as an ISO 21973 certification that it described as a first in the market. These developments reinforce the company’s positioning as a quality-driven specialist in advanced therapy logistics. For international equity investors, Cryoport remains a niche healthcare infrastructure name tied to the long-term growth of cell and gene therapy, while still exposed to the timing, funding, and commercialization cycles of biotech customers. ([cryoport.com](https://www.cryoport.com/news-blog-cryoport-systems-wins-best-cell-gene-therapy-supplier-award-at-apcgtea-2025/?utm_source=openai))